- Tytuł:
- Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti–Tumor Necrosis Factor Agents
- Autorzy:
- Źródło:
- In Clinical Gastroenterology and Hepatology February 2016 14(2):242-250
- Czasopismo naukowe